Mylan is unable to rule out the possibility that Esme-28 was impacted by the same packaging issue involving Freya-28, wherein an additional placebo tablet was found in place of an active tablet in one blister pack.
Type I Risk for patients who should not get pregnant, whether for medical reasons or exposure to agents detrimental to a developing fetus, and Type II risk for the general population.